1 results match your criteria: "University of Ottawa Heart Institute and the University of Ottawa[Affiliation]"
Does FDG PET-assisted management of patients with left ventricular dysfunction improve quality of life? A substudy of the PARR-2 trial.
Can J Cardiol
March 2012
Molecular Function and Imaging Program, The National Cardiac PET Centre, Division of Cardiology, University of Ottawa Heart Institute and the University of Ottawa, Ottawa, Ontario, Canada.
Background: Patients with left ventricular dysfunction whose management is directed by F-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging may have a quality of life (QOL) benefit over standard care.
Methods: Among 430 patients randomized in the PET and Recovery Following Revascularization (PARR)-2 trial to FDG PET-assisted management vs standard, QOL scores were obtained using the European Quality of Life-5 Dimensions (EQ-5D) in 427 patients at baseline (FDG PET n = 216; standard n = 211) and 355 patients at 12-month follow-up (FDG PET n = 184; standard n = 171). EQ-5D scores between FDG PET and standard arms were compared using mixed model repeated measures (MMRM).